The Charles T. Campbell Eye Microbiology Lab
UPMC | University of Pittsburgh Medical CenterUniversity of Pittsburgh Schools of the Health Sciences
HomeAbout UsLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchContact Us

2010 OMIG, Abstract 13

OMIG Main Page | 2010 Abstracts | < Previous| Next >

A comparison of the in vitro susceptibility profiles of telavancin, vancomycin, moxifloxacin and gatifloxacin against Gram positive keratitis isolates including methicillin resistant Staphylococcus aureus (MRSA)
M. Shah, W. Perez, E. Wu, J. Seedor, R. Koplin, D. Ritterband,  Depts. of Ophthalmology and Laboratory Medicine, The New York Eye and Ear Infirmary, NY, NY and New York Medical College, Valhalla, NY

Purpose: To determine the in-vitro susceptibility profile of Telavancin, a novel lipoglycopeptide antimicrobial agent against gram positive keratitis isolates.
Methods: 9 Methicillin resistant Staph aureus (MRSA), 6 Methicillin sensitive Staph aureus (MSSA), 5 Methicillin resistant Staph epidermidis (MRSE),  3 Methicillin sensitive Staph epidermidis (MSSE), 4 Strep viridans group,  2 Enterococcus spp and 1 Staph hominus isolate from cases of corneal ulcers were tested for in vitro susceptibility against telavancin, moxifloxacin, gatifloxacin, and vancomycin using a Kirby Bauer method.  
Results:  Telavancin was active against all gram positive strains tested with zones of inhibition ranging from (18-28mm). Vancomycin was also active against all isolates. Gatifloxacin and moxifloxacin were active against 25/30 isolates. There were 4 isolates of MRSA and 1 isolate of MRSE resistant to both fluoroquinolone antibiotics. 
Conclusions: Telavancin is a promising new agent for gram-positive infections and may offer an alternative to vancomycin for MRSA-associated infections.
Disclosure Code:  N

Top of Page